Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus best supportive care versus placebo in previously treated advanced gastric cancer
NL-OMON35532Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric cancer (GC) and gastric adenocarcinoma comparing Everolimus plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Overall survival. Planned start Jun 2009; status: not yet recruiting.
02
Drugs
everolimus
03
Conditions
gastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on NL-OMON35532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35532.